Biovex, which was founded in 1998, develops new vaccines used to treat cancer and chronic infectious diseases. The company has two proprietary platforms, namely OncoVEX and ImmunoVEX, based on genetic manipulation of the herpes simplex virus (HSV). Biovex recently completed a Phase II clinical trial for the treatment of melanoma with its OncoVEX GM-CSF product. The results of this trial showed that the product was capable of inducing a lasting response in a large proportion of the patients treated. The company is currently carrying out Phase III trials for this indication.
January 2011: Amgen completed the acquisition of BioVex for total consideration of up to $1 billion should it reach its milestones.